CG Oncology CGON 深 滬
已收盤 08-07 16:00:00 美东时间
75.10
+0.250
+0.33%
華盛通- 最 高76.20
- 今 開74.97
- 成交量 61.16万股
- 最 低 73.51
- 昨 收 74.85
- 總市值 66.24亿
- 52周最高 77.00
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 24.85
- 委 比 -63.06%
- 總股本 8820.25万
- 歷史最高 77.00
- 量 比 0.78
- 振 幅 3.59%
- 歷史最低 14.80
- 每 手 1
- 風險率 14.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
08-07 21:12
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
财报速睇 | CG Oncology 2026财年Q2营收0.01亿美元，同比增长（去年同期为零）；归母净利润亏损0.79亿美元，同比亏损扩大90.8%
华盛资讯8月6日讯，CG Oncology公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比增长（去年同期为零），归母净利润亏损0.79亿美元，同比亏损扩大90.8%。
08-06 21:25
财报速睇 | CG Oncology 2026财年Q2营收0.01亿美元，同比增长；归母净利润亏损0.79亿美元，同比亏损扩大90.8%
华盛资讯8月6日讯，CG Oncology公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比增长，归母净利润亏损0.79亿美元，同比亏损扩大90.8%。
08-06 20:54
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $1.157 million w...
08-06 20:53
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C trial results in *The Lancet Oncology*, showing cretostimogene grenadenorepvec monotherapy achieved 75.5% complete response rates in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. With a median duration of response of 27.9 months, 89% of patients maintained bladder preservation at 12 months and 81% at 24 months. The treatment demonstrated ...
07-27 22:45
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value ...
07-17 04:38
ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE)...
07-17 04:38
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ:CGON) with a Peer Perform rating.
05-19 20:11
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
